Childhood kidney tumor trial using anthracycline chemo
Treatments studied
Part of Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a combination of anthracycline chemotherapy drugs (including doxorubicin) for children with nephroblastoma, a kidney cancer. It aims to improve treatment outcomes and confirm the best way to use these medicines in pediatric care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 6 months and 14 years old
- Your child has been diagnosed with nephroblastoma confirmed by pathology (tissue test)
- Your child is recommended to receive anthracycline chemotherapy, including doxorubicin, per the Chinese nephroblastoma treatment plan
- Your child should be able to follow the study plan (good compliance) and has provided consent/assent
- Your child has not had chemotherapy or heart-harming (cardiotoxic) kidney/heart-damaging medicines in the last 4 weeks
- Your child has not joined another clinical trial in the last 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
This study tests two different chemotherapy combinations for children whose kidney tumor has spread to the lungs (or looks highly suspicious for spread). You may be assigned to either the standard plan or an experimental plan, and the goal is to see which works better and is safest.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial looks at what treatment recommendations work best for children with a nephroblastoma (Wilms tumor) that is in only one kidney and has not been treated yet. It may help doctors choose the best next steps for care while the child’s overall health supports treatment.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or not responded to treatment. The goal is to see if this combination can shrink or control the tumor.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
Hear when a new 0.5-14 Year Old Children With Nephroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.